{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:43:28Z","timestamp":1781664208796,"version":"3.54.5"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.leukres.2022.106820","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T15:27:56Z","timestamp":1646666876000},"page":"106820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future"],"prefix":"10.1016","volume":"115","author":[{"given":"Daniel I.","family":"Nathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj M.","family":"El Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106820_bib1","doi-asserted-by":"crossref","unstructured":"D.A. Arber A. Orazi R. Hasserjian J. Thiele M.J. Borowitz M.M.L. Beau C.D. Bloomfield M. Cazzola J.W. Vardiman. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood, 127, 20, 2016, pp. 2391\u20132405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"10.1016\/j.leukres.2022.106820_bib2","unstructured":"World Health Organization Classification of tumours: Pathology & genetics: Tumours of haematopoietic and lymphoid tissues 2001 IARCPress Lyon."},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.11581","article-title":"JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"93","author":"Schmitt-Graeff","year":"2008","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2022.106820_bib4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41379-020-0624-y","article-title":"Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2\/MPL\/CALR) and SF3B1","volume":"34","author":"Ok","year":"2021","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.leukres.2022.106820_bib6","article-title":"Myelodysplastic syndrome\/myeloproliferative neoplasms with ringed sideroblasts and thrombocytosis (MDS\/MPN RS-T)\u2013a case report with literature review on diagnosis and management","volume":"8","author":"Niazi","year":"2021","journal-title":"Ann. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2022.106820_bib7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2022.106820_bib8","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations","volume":"100","author":"Jeromin","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2022.106820_bib9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood.2021014276","article-title":"Myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts, thrombocytosis, and mutated JAK2\/SF3B1 without anemia","volume":"139","author":"Neumann","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106820_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2018.11.022","article-title":"Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms","volume":"86","author":"Boiocchi","year":"2019","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.leukres.2022.106820_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1309\/AJCPT0B6VEQPRCOA","article-title":"Refractory anemia with ring sideroblasts associated with marked ThrombocytosisA mixed group exhibiting a spectrum of morphologic findings","volume":"135","author":"Gurevich","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.leukres.2022.106820_bib12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3324\/haematol.2011.044628","article-title":"Ring sideroblasts and sideroblastic anemias","volume":"96","author":"Cazzola","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2022.106820_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS\u2010T) and the role of next\u2010generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2022.106820_bib14","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jclinpath-2019-205895","article-title":"Somatic SF3B1 mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia","volume":"72","author":"Foy","year":"2019","journal-title":"J. Clin. Pathol."},{"issue":"15","key":"10.1016\/j.leukres.2022.106820_bib15","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2022.106820_bib16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2012-09-399725","article-title":"Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms","volume":"121","author":"Cazzola","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106820_bib17","article-title":"JAK2\/CALR\/SF3B1 triple-mutated myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: evidence of a pre-JAK2 clone","volume":"100","author":"Yasuda","year":"2020","journal-title":"Leuk. Res"},{"issue":"17","key":"10.1016\/j.leukres.2022.106820_bib18","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2022.106820_bib19","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/sj.leu.2404373","article-title":"The JAK2 V617F mutation is rare in RARS but common in RARS-T","volume":"20","author":"Ceesay","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2022.106820_bib20","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2006-02-005751","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation","volume":"108","author":"Szpurka","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2022.106820_bib21","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2006-03-008227","article-title":"The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS)","volume":"108","author":"Boissinot","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2022.106820_bib22","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.leu.2404405","article-title":"High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"20","author":"Renneville","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-139983","article-title":"Genomic and transcriptomic differences of myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)","volume":"136","author":"Bravo","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2022.106820_bib24","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Bros\u00e9us","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106820_bib25","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.280463","article-title":"SF3B1-mutant myelodysplastic syndrome\/myeloproliferative neoplasms: a unique molecular and prognostic entity","author":"Mangaonkar","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2022.106820_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-022-00622-8","article-title":"Myelodysplastic\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients","volume":"12","author":"Mangaonkar","year":"2022","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.leukres.2022.106820_bib27","doi-asserted-by":"crossref","first-page":"E109","DOI":"10.1002\/ajh.26448","article-title":"Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS\/MPN-RS-T","volume":"97","author":"Mangaonkar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2022.106820_bib28","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med."},{"issue":"9","key":"10.1016\/j.leukres.2022.106820_bib29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp. Hematol."},{"issue":"22","key":"10.1016\/j.leukres.2022.106820_bib30","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2022.106820_bib31","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/leu.2016.216","article-title":"Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis","volume":"30","author":"Patnaik","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2022.106820_bib32","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk\u2010stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2022.106820_bib33","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2022.106820_bib34","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2022.106820_bib35","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2022.106820_bib36","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2022.106820_bib37","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstrom-Lindberg","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106820_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2019.01.021","article-title":"Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: a systematic review","volume":"136","author":"Affentranger","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"14","key":"10.1016\/j.leukres.2022.106820_bib39","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2016.71.3271","article-title":"Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents","volume":"35","author":"Park","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib40","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2019-126199","article-title":"Response to erythropoiesis stimulating agents in patients with WHO-defined myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T)","volume":"134","author":"Antelo","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease","volume":"153","author":"Palmer","year":"2010","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib42","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood-2018-99-110237","article-title":"Lenalidomide is effective treatment option for patients with refractory anemia with ring sideroblasts and thrombocytosis","volume":"132","author":"Melody","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106820_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106430","article-title":"Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia","volume":"97","author":"Feld","year":"2020","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/j.leukres.2022.106820_bib44","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106820_bib45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2022.106820_bib46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/17474086.2021.1947791","article-title":"Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts","volume":"14","author":"Schulz","year":"2021","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-137232","article-title":"Efficacy and safety of luspatercept treatment in patients with myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T): a retrospective analysis from the medalist study","volume":"136","author":"Komrokji","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2022.106820_bib48","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of luspatercept in patients with transfusion-dependent beta-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2022.106820_bib49","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.leukres.2022.106820_bib50","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-142084","article-title":"Clinical outcomes with hypomethylating agents in patients with myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T); a case series","volume":"136","author":"Siddiqui","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2022.106820_bib52","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"New Engl. J. Med."},{"issue":"25","key":"10.1016\/j.leukres.2022.106820_bib53","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents","volume":"34","author":"Santini","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2022.106820_bib54","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/leu.2015.296","article-title":"Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion","volume":"30","author":"Toma","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2022.106820_bib55","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.20.01691","article-title":"Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin","volume":"39","author":"List","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106820_bib56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2010-01-263087","article-title":"Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis","volume":"116","author":"Huls","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106820_bib57","article-title":"Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia","volume":"2013","author":"Taylor","year":"2013","journal-title":"Case Rep. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2022.106820_bib58","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.4081\/hr.2016.6592","article-title":"Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K\/L mutations","volume":"8","author":"Keen","year":"2016","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.leukres.2022.106820_bib59","first-page":"5317","article-title":"Efficacy of lenalidomide in myelodysplastic\/myeloproliferative neoplasms with ring sideroblasts","volume":"130","author":"Girodon","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib60","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1182\/blood-2018-99-117266","article-title":"Characteristics and role of lenalidomide therapy in patients with myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis","volume":"132","author":"Naqvi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106820_bib61","first-page":"1","article-title":"Treatment outcomes for patients with myelodysplastic syndrome\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis","author":"Komrokji","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.leukres.2022.106820_bib62","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/17474086.2013.814456","article-title":"Iron chelation therapy in myelodysplastic syndromes: where do we stand?","volume":"6","author":"Mitchell","year":"2013","journal-title":"Expert Rev. Hematol."},{"issue":"17","key":"10.1016\/j.leukres.2022.106820_bib63","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","article-title":"Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome","volume":"30","author":"List","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2022.106820_bib64","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.leukres.2009.12.004","article-title":"Gfm, Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies)","volume":"34","author":"Rose","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2022.106820_bib65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.leukres.2017.11.005","article-title":"Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?","volume":"64","author":"Wong","year":"2018","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.leukres.2022.106820_bib66","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial","volume":"172","author":"Angelucci","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.leukres.2022.106820_bib67","first-page":"239","article-title":"A review on iron chelators in treatment of iron overload syndromes","volume":"10","author":"Mobarra","year":"2016","journal-title":"Int J. Hematol. Oncol. Stem Cell Res."},{"key":"10.1016\/j.leukres.2022.106820_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.13","article-title":"Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis","volume":"6","author":"Tefferi","year":"2016","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.leukres.2022.106820_bib69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.leukres.2022.106820_bib70","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2022.106820_bib71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2022.106820_bib72","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review","volume":"167","author":"Chu","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.leukres.2022.106820_bib73","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2022.106820_bib74","doi-asserted-by":"crossref","first-page":"914","DOI":"10.20452\/pamw.3211","article-title":"Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients","volume":"125","author":"Mital","year":"2015","journal-title":"Pol. Arch. Med. Wewn."},{"issue":"10","key":"10.1016\/j.leukres.2022.106820_bib75","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood.V91.10.3623","article-title":"Clinical significance of inhibitors in acquired von Willebrand syndrome","volume":"91","author":"Mohri","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2022.106820_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071746","article-title":"Essential thrombocythemia and acquired von willebrand syndrome: the shadowlands between thrombosis and bleeding","volume":"12","author":"Awada","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.leukres.2022.106820_bib77","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11899-020-00588-z","article-title":"Thrombocytosis and thrombosis: is there really a correlation?","volume":"15","author":"Galvez","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"17","key":"10.1016\/j.leukres.2022.106820_bib78","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2022.106820_bib79","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V99.5.1602","article-title":"Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia","volume":"99","author":"Tomer","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","article-title":"a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group","volume":"92","author":"Anagrelide","year":"1992","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"New Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2022.106820_bib82","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2022.106820_bib83","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1517\/14656566.2015.1036029","article-title":"Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera","volume":"16","author":"Kremyanskaya","year":"2015","journal-title":"Expert Opin. Pharm."},{"issue":"18","key":"10.1016\/j.leukres.2022.106820_bib84","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2022.106820_bib85","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2022.106820_bib86","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2022.106820_bib87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2016.266","article-title":"Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the chronic malignancy working party of the EBMT","volume":"52","author":"Robin","year":"2017","journal-title":"Bone Marrow Transpl."},{"issue":"12","key":"10.1016\/j.leukres.2022.106820_bib88","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106820_bib89","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1182\/blood-2019-130722","article-title":"Abnl Marro: an international cooperative trial for patients with MDS\/MPN overlap syndromes","volume":"134","author":"Savona","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2022.106820_bib90","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1038\/bcj.2016.13","article-title":"Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis","volume":"6","author":"Tefferi","year":"2016","journal-title":"Blood Cancer Journal"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:03Z","timestamp":1758934923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":90,"alternative-id":["S0145212622000467"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106820","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106820"}}